Showing results (41-50 of 272) with videos related to
Sort By:
Pageof 28
Cancer|April 10, 2004
Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignanciesAmit Panwalkar, Srdan Verstovsek, Francis GilesClinical Lymphoma & Myeloma|March 27, 2007
Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemiaRonan Swords, Yesid Alvarado, Francis GilesCancers|June 29, 2019
Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer ModelsDevalingam Mahalingam, Jennifer S Carew, Claudia M Espitia, et al.Journal of Cellular and Molecular Medicine|November 25, 2010
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinibKevin R Kelly, Jeffrey Ecsedy, Ernest Medina, et al.Cancer Chemotherapy and Pharmacology|March 15, 2017
A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanomaDevalingam Mahalingam, Christos Fountzilas, Jennifer Moseley, et al.British Journal of Cancer|June 23, 2022
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)Sukeshi Patel Arora, Laura Tenner, John Sarantopoulos, et al.Investigational New Drugs|January 20, 2017
Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?Christos Fountzilas, Selena Stuart, Brian Hernandez, et al.Oncotarget|November 18, 2015
Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancerSweta Mishra, Qin Tai, Xiang Gu, et al.The Journal of Biological Chemistry|December 15, 2010
Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosisJennifer S Carew, Claudia M Espitia, Juan A Esquivel, et al.Cancer|July 27, 2022
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01Vaibhav Sahai, Kent A Griffith, Muhammad S Beg, et al.Pageof 28